FDA’s Ocaliva Blow Spells Changes In Primary Biliary Cholangitis Landscape
Gilead’s Livdelzi, Ipsen’s Iqirvo To Gain
The landscape for primary biliary cholangitis or cirrhosis, PBC, is set to change if Intercept withdraws Ocaliva, which received its fourth safety alert from the US FDA and lost conditional marketing authorization in EU. Pink Sheet studies data from Citeline’s Pharmaprojects and separately Evaluate Pharma to reveal a promising clinical trials landscape and a sizeable market
